News

SHAREHOLDER WARNING: Pomerantz legislation agency is investigating claims on behalf of traders in Verrica Prescribed drugs Inc. – VRCA – Yahoo Finance

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "NEW YORK, September 7, 2020 / PRNewswire / – Pomerantz LLP is investigating claims on behalf of investors in Verrica Pharmaceuticals Inc. ("Verrica" ​​or the "Company") (NASDAQ: VRCA). We recommend that you contact these investors Robert S. Willoughby at the rswilloughby@pomlaw.com or 888-476-6529, extension 7980. "data-reactid =" 12 ">NEW YORK, September 7, 2020 / PRNewswire / – Pomerantz LLP is investigating claims on behalf of investors in Verrica Pharmaceuticals Inc. ("Verrica" ​​or the "Company") (NASDAQ: VRCA). We recommend that you contact these investors Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Verrica and any of its officers and / or directors have committed securities fraud or other illegal business practices.

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "(Click here for information on how to participate in the class action.) "data-reactid =" 14 "> (Click here for information on joining the class action.)

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "On June 29, 2020Verrica announced that it had received a letter from the US Food and Drug Administration ("FDA ") has received treatment for molluscum contagiosum. According to the company, deficiencies were cited in the letter that preclude a discussion of the labeling and post-marketing requirements / obligations at this point in time. While Verrica stated that the letter did not make specific points, she noted that the FDA's regular requests for additional information related to aspects of chemistry, manufacture, and control of the drug-device combination. The company also stated that its ability to process the requests had been "severely affected" by COVID-19 disruptions. "data-reactid =" 19 "> On June 29, 2020Verrica announced that it had received a letter from the US Food and Drug Administration ("FDA ") has received treatment for molluscum contagiosum. According to the company, deficiencies were cited in the letter that preclude a discussion of the labeling and post-marketing requirements / obligations at this point in time. While Verrica stated that the letter did not make specific points, she noted that the FDA's regular requests for additional information related to aspects of chemistry, manufacture, and control of the drug-device combination. The company also stated that its ability to process the requests had been "severely affected" by COVID-19 disruptions.

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Following this announcement, Verrica's share price fell $ 3.06 per share, or 21.75% to close on $ 11.01 per share on June 30, 2020. "data-reactid =" 20 "> After this announcement, Verrica's share price fell $ 3.06 per share, or 21.75% to close on $ 11.01 per share on June 30, 2020.

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "The company Pomerantz with offices in new York, Chicago, los Angeles, and Paris is recognized as a leader in corporate, securities and antitrust litigation. Established by the late Abraham L. PomerantzPomerantz Company, known as the dean of class action, pioneered class action lawsuits. Today, more than 80 years later, Pomerantz continues its tradition of fighting for the rights of victims of securities fraud, fiduciary violations and corporate misconduct. The company has received numerous millions of dollars in damages on behalf of class members. See www.pomerantzlaw.com. "data-reactid =" 21 "> The Pomerantz company with offices in new York, Chicago, los Angeles, and Paris is recognized as a leader in corporate, securities and antitrust litigation. Established by the late Abraham L. PomerantzPomerantz Company, known as the dean of class action, pioneered class action lawsuits. Today, more than 80 years later, Pomerantz continues its tradition of fighting for the rights of victims of securities fraud, fiduciary violations and corporate misconduct. The company has received numerous millions of dollars in damages on behalf of class members. See www.pomerantzlaw.com.

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 extension 7980 "data-reactid =" 22 "> CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Show original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-verrica-pharmaceuticals-inc—vrca-301125162. html"data-reactid =" 35 "> show original content: http: //www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of – verrica-pharmaceuticals-inc — vrca-301125162.html

SOURCE Pomerantz LLP

0 Comments
Share

labsurlab

Reply your comment

Your email address will not be published. Required fields are marked*